Email
Print
Anti-Hypertensive Drugs Market - By Therapeutic Class (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Alpha Blockers, Renin Inhibitors, Calcium Channel Blockers, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Stores, Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027
Anti-Hypertensive Drugs Market Overview
Anti-Hypertensive Drugs Market size is estimated to reach $28.7 billion
by 2027, growing at a CAGR of 3.7% during the forecast period 2022-2027. Antihypertensive
drugs are medications that are utilized to treat hypertension (high blood
pressure) There are distinct kinds of antihypertensive drugs that perform
differently to reduce elevated blood pressure. Ethacrynic acid is a loop diuretic that acquired
U.S. Food And Drug Administration (FDA) endorsement for extensive application
in 1967. Angiotensin-converting
enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are the most typically
prescribed anti-hypertensive medicines in the U.S. The application of thiazide
diuretics for the treatment of high blood pressure minimized blood pressure by
9 points in the upper number termed systolic blood pressure and 4 points in the
lower number termed diastolic blood pressure. Diverse thiazide medications have
analogous effects in reducing blood pressure and thiazides reduce systolic
blood pressure more than other classes of antihypertensive medications. Calcium
channel blocker is a medicine that reduces blood pressure and treats additional
conditions like chest pain and erratic heartbeat.
The serious impact on people with hypertension owing to the COVID-19
pandemic is set to drive the Anti-Hypertensive Drugs Market. The soaring
initiatives by private and government organizations and the surging awareness
regarding hypertension involving the application of thiazide diuretics worldwide are
set to propel the growth of the Anti-Hypertensive Drugs Market during the
forecast period 2022-2027. This represents the Anti-Hypertensive Drugs Industry
Outlook.
Report Coverage
The report: “Anti-Hypertensive Drugs Market Forecast
(2022-2027)”, by Industry ARC, covers an in-depth analysis of the following
segments of the Anti-Hypertensive Drugs Market.
By Therapeutic Class: Diuretics, Angiotensin
Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta
Blockers, Alpha Blockers, Renin Inhibitors, Calcium Channel Blockers, Others.
By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Stores, Others.
By Geography: North
America (the U.S, Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain,
Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India,
Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil,
Argentina, Chile, Colombia, Rest of South America), and Rest Of The World
(Middle East, Africa).
Key Takeaways
- Geographically, the North American Anti-Hypertensive Drugs Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the soaring predominance of hypertension and ailments bringing about hypertension which may require the application of calcium channel blockers in the North American region.
- Anti-Hypertensive Drugs Market growth is being driven by the increasing predominance of hypertension across the world requiring the application of calcium channel blockers and the ability of certain medications to induce hypertension in patients with additional ailments. However, the termination of patent of numerous principal medications together with side-effects related to hypertension treatment is one of the major factors hampering the growth of the Anti-Hypertensive Drugs Market.
Anti-Hypertensive Drugs Market: Market Share (%) by Region, 2021
Anti-Hypertensive Drugs Market Segment Analysis – By Therapeutic Class:
The Anti-Hypertensive Drugs
Market based on therapeutics class can be further segmented into Diuretics, Angiotensin Converting Enzyme (ACE)
Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Alpha
Blockers, Renin Inhibitors, Calcium Channel Blockers, and Others. The Diuretics Segment held the largest market
share in 2021. This growth is owing to the surging application of
diuretics to minimize sodium and water in the body by activating the kidneys to
discharge more sodium through the urine resulting in a reduction in blood
pressure. Thiazide Diuretics are utilized to treat hypertension. The soaring
efficiency, reduced cost and reduced chances of side-effects in comparison with
other therapeutic classes are further propelling the growth of the Diuretics segment.
Furthermore, the Calcium Channel Blockers segment is estimated to grow
with the fastest CAGR of 4.3% during the forecast period 2022-2027 owing to
the soaring global demand for calcium channel blockers owing to their reduced
side-effects in comparison with other antihypertensive drugs and their
advantages like their positive impact on complete health and delaying the
advancement of chronic renal failure.
Anti-Hypertensive Drugs Market Segment Analysis – By Distribution Channel:
The Anti-Hypertensive
Drugs Market based on distribution channels can be further segmented into Retail Pharmacies, Hospital Pharmacies, Online Stores, and Others. The Retail Pharmacies segment held the largest market
share in 2021. This growth is owing to the
soaring application of retail pharmacies resulting in enhanced patient
satisfaction. Antihypertensive medications like thiazide diuretics may be
available in retail pharmacies. Pharmacists with access to full patient
histories-inclusive of the specialists they consulted, the medicines they consumed,
and more-are better able to counsel patients on safe application. Collaboration
may also bring down the outpatient medicine errors, an enormous hazard when
patients leap from pharmacy to pharmacy post clearance. The care team
collaboration to enhance patient outcomes is thus further propelling the growth
of this segment.
Furthermore, the Online segment is estimated
to grow with the fastest CAGR of 4.5% during the forecast period 2022-2027 owing to the surging
application of online pharmacies like PharmEasy offering antihypertensive drugs
like thiazide diuretics including Chlorthalidone.
Anti-Hypertensive Drugs Market Segment Analysis – By Geography:
The Anti-Hypertensive
Drugs Market based on geography can be further segmented into North America,
Europe, Asia-Pacific, South America, and the Rest of the World. North America (Anti-Hypertensive
Drugs Market) held the largest share with 35% of the overall market in 2021.
The growth of this region is owing to the increasingly
effortless application of antihypertensive medications like thiazide diuretics
in the region. The surging
population of the elderly in conjunction with their increased susceptibility to
hypertension is further driving the growth of the Anti-Hypertensive Drugs Market in
this region. The existence of key players like Pfizer, Inc. in the U.S. in the
region is further propelling the growth of the Anti-Hypertensive Drugs Market
in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like soaring awareness of antihypertensive medications like thiazide diuretics in the Asia-Pacific region. The proliferation in government schemes and initiatives for enhancing the healthcare sector, integrated with the surging predominance of Chronic Obstructive Pulmonary Disease (COPD) in China is further fueling the progress of the Anti-Hypertensive Drugs Market in the Asia-Pacific region.
Anti-Hypertensive Drugs Market Drivers
Surging Applications Of Thiazide Diuretics Against Hypertension Are Projected To Drive The Growth Of Anti-Hypertensive Drugs Market:
There are numerous causes of hypertension (high blood pressure) inclusive of progressive age, smoking, and obesity. Occasionally, the fundamental cause of hypertension cannot be decided, leading to a diagnosis of idiopathic hypertension. Unregulated hypertension will ultimately cause damage to the heart, kidneys, and eyes. Thiazide diuretics are principally utilized to treat hypertension (high blood pressure) and edema (swelling) brought about by water overload and some conditions connected to irregular calcium metabolism. Thiazides and thiazide-like diuretics have been in consistent use since their launch in 1958. Typically, thiazides and thiazide-like diuretics minimize the hazard of loss of life, stroke, heart attack, and heart failure owing to hypertension. Guidelines in the U.S. advocate thiazides as a first-line treatment for hypertension (JNC VIII). A systematic examination by the Cochrane Collaboration particularly advocated that low-dose thiazides be utilized as the beginning pharmacological therapy for high blood pressure. Low-dose thiazides are more efficient at treating hypertension than beta-blockers and are identical to angiotensin-converting enzyme (ACE) inhibitors. Thiazides are an advocated treatment for hypertension in Europe (ESC/ESH). Thiazides should be regarded as beginning treatment if the patient has a soaring hazard of establishing heart failure. Thiazide-type diuretics (chlorthalidone and indapamide) have been displayed to be superior in averting cardiovascular disease at a reduced cost. Suggestions are to begin them as first-line treatment for hypertension. The surging applications of thiazide diuretics against hypertension are therefore fuelling the growth of the Anti-Hypertensive Drugs Market during the forecast period 2022-2027.
Soaring Applications Of Calcium Channel Blocker Against Hypertension Are Expected To Boost The Demand Of Anti-Hypertensive Drugs Market:
As per World Health Organization, an approximated 1.28 billion mature grown-ups aged 30-79 years globally have hypertension, most (two-thirds) residing in low- and middle-income countries. A calcium channel blocker is the medication that is utilized against hypertension and chest pain. It slows the calcium motion that assists in broadening the blood vessels thereby minimizing blood pressure and making it effortless for the heart to pump the blood. The population of the elderly is increasing at an accelerated pace owing to medical progress and the curbing of incessant ailments. Calcium channel blocker has been demonstrated to be efficient in this condition in the elderly. The success relies on the technique of action, and on the physiological alterations recognized, and on the aging process itself, which involves cardiac hypertrophy, calcification of cardiac valves, and a reduction in the excitation-conduction system. Calcium channel blocker has been demonstrated to be efficient in any age group for the handling of hypertension and is safe for use in elderly patients. This medication obstructs L-type calcium channels, with the long-acting or most-recent generation dihydropyridines being the most efficient of this group. Numerous investigations, inclusive of SYST-EUR2, NORDIL, and STOP-2, have displayed the efficiency of these medications in elderly patient. The prescribing of long-acting calcium channel blocker medications in a single dose is the most suggested. The security in the application of this medication group has been established in the treatment of hypertension in elderly patient, with a level of efficiency identical to additional extensively utilized medications. These kinds of soaring applications of calcium channel blockers against hypertension are driving the growth of the Anti-Hypertensive Drugs Market during the forecast period 2022-2027.
Anti-Hypertensive Drugs Market Challenges
The Hazard Of Falls And/Or Fractures In The Elderly Is Hampering The Growth Of The Anti-Hypertensive Drugs Market:
Antihypertensive medications utilized to treat hypertension in the elderly may bring about and/or aggravate pre-existing orthostatic hypotension (OH) leading to poor balance, dizziness, tiredness, weakness, and even falls with consequent injury inclusive of fractures. The treatment of hypertension in the elderly needs further explanation as numerous international guidelines are inconstant in offering suggestions on optimal BP goals for both initiations of therapy and for treatment in the elderly owing to the restricted result data from randomized controlled trials (RCTs) in this population. While the guidelines concentrate on the morbidity and mortality advantages from the treatment of hypertension, it is vital to note that there are also clinical investigations that have displayed possible hazards related to the application of antihypertensive medications in hypertensive elderly patients. Elderly patients classically treated in clinical practice tend to be fragile, with diversified comorbidities and polypharmacy. These kinds of patients are frequently not included in clinical trials assessing antihypertensive treatment. Furthermore, elderly hypertensive patients are more likely than their younger equivalents to have orthostatic hypotension (OH). Consequently, elderly hypertensive patients are at a heightened hazard of falls and/or fractures succeeding antihypertensive medication introduction. Thus, handling antihypertensive treatment of the elderly may be challenging in clinical practice in terms of balancing the recognized advantages with the possible hazards of therapy. This issue is hampering the growth of the Anti-Hypertensive Drugs Market.
Anti-Hypertensive Drugs Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Anti-Hypertensive Drugs Market. Key companies of this market are:
- C.H. Boehringer Sohn AG & Ko. KG
- Noden Pharma
- Merck & Co. Inc.
- Daiichi Sankyo Company Limited
- Novartis AG
- Johnson & Johnson Ltd,
- Ranbaxy Laboratories Limited
- Sanofi SA
- Pfizer, Inc.
- AstraZeneca plc
Recent Developments
- In November 2021, Daiichi Sankyo Company, introduced DELYTACT® (teserpaturev/G47)*1, an oncolytic virus established by the firm in collaboration with Professor Tomoki Todo of the Institute of Medical Science, The University of Tokyo. DELYTACT® accepted conditional and time-limited marketing endorsement in Japan as a regenerative medical product for the treatment of malignant glioma in June 2021 based on outcomes from a Japanese phase 2 clinical trial (investigator-initiated trial) in patients with glioblastoma*2 (a kind of malignant glioma*3) directed by Dr. Todo. For the time being, DELYTACT® will be commercially accessible only at hospitals that acted as trial sites.
- In June 2021, C.H. Boehringer Sohn AG & Ko. KG and Eli Lilly & Company declared to have accepted marketing permission from the European Commission, for their incessant heart failure treatment medication, Jardiance® (Empagliflozin). The current advancement is an expansion of a positive endorsement accepted from the Committee for Medicinal Products for Human Use (CHMP). The currently endorsed Jardiance will presently be utilized by mature grownups enduring incessant heart failure and minimized ejection fraction (systolic heart failure).
- In June 2021, Merck termed MSD outside the U.S. and Canada, declared that it has finished the spinoff of Organon & Co. (Organon). Merck’s objective with the spinoff was to build two patient-focused firms with an improved strategic and operational focus, enhanced agility, abridged operating models, optimized capital structures, and enhanced financial profiles. Merck trusts the transaction will convey important advantages for both Merck and Organon and develop a value for Merck shareholders.
Related Reports
Hypertension Drugs Market
Report Code: HCR 71145
Generic Drugs Market –
Forecast (2022 - 2027)
Report Code: HCR 0217
For more Lifesciences and Healthcare related reports, please click here
Table 1: Antihypertensive Drugs Market Overview 2021-2026
Table 2: Antihypertensive Drugs Market Leader Analysis 2018-2019 (US$)
Table 3: Antihypertensive Drugs Market Product Analysis 2018-2019 (US$)
Table 4: Antihypertensive Drugs Market End User Analysis 2018-2019 (US$)
Table 5: Antihypertensive Drugs Market Patent Analysis 2013-2018* (US$)
Table 6: Antihypertensive Drugs Market Financial Analysis 2018-2019 (US$)
Table 7: Antihypertensive Drugs Market Driver Analysis 2018-2019 (US$)
Table 8: Antihypertensive Drugs Market Challenges Analysis 2018-2019 (US$)
Table 9: Antihypertensive Drugs Market Constraint Analysis 2018-2019 (US$)
Table 10: Antihypertensive Drugs Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Antihypertensive Drugs Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Antihypertensive Drugs Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Antihypertensive Drugs Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Antihypertensive Drugs Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Antihypertensive Drugs Market Value Chain Analysis 2018-2019 (US$)
Table 16: Antihypertensive Drugs Market Pricing Analysis 2021-2026 (US$)
Table 17: Antihypertensive Drugs Market Opportunities Analysis 2021-2026 (US$)
Table 18: Antihypertensive Drugs Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Antihypertensive Drugs Market Supplier Analysis 2018-2019 (US$)
Table 20: Antihypertensive Drugs Market Distributor Analysis 2018-2019 (US$)
Table 21: Antihypertensive Drugs Market Trend Analysis 2018-2019 (US$)
Table 22: Antihypertensive Drugs Market Size 2018 (US$)
Table 23: Antihypertensive Drugs Market Forecast Analysis 2021-2026 (US$)
Table 24: Antihypertensive Drugs Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Antihypertensive Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 26: Antihypertensive Drugs Market By Type, Revenue & Volume,By Diuretics, 2021-2026 ($)
Table 27: Antihypertensive Drugs Market By Type, Revenue & Volume,By Angiotensin Converting Enzyme (ACE) Inhibitors, 2021-2026 ($)
Table 28: Antihypertensive Drugs Market By Type, Revenue & Volume,By Angiotensin Receptor Blockers (ARBs), 2021-2026 ($)
Table 29: Antihypertensive Drugs Market By Type, Revenue & Volume,By Calcium Channel Blockers, 2021-2026 ($)
Table 30: Antihypertensive Drugs Market By Type, Revenue & Volume,By Beta Blockers, 2021-2026 ($)
Table 31: North America Antihypertensive Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 32: South america Antihypertensive Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 33: Europe Antihypertensive Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 34: APAC Antihypertensive Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 35: Middle East & Africa Antihypertensive Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 36: Russia Antihypertensive Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 37: Israel Antihypertensive Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 38: Top Companies 2018 (US$)Antihypertensive Drugs Market, Revenue & Volume
Table 39: Product Launch 2018-2019Antihypertensive Drugs Market, Revenue & Volume
Table 40: Mergers & Acquistions 2018-2019Antihypertensive Drugs Market, Revenue & Volume
List of Figures
Figure 1: Overview of Antihypertensive Drugs Market 2021-2026
Figure 2: Market Share Analysis for Antihypertensive Drugs Market 2018 (US$)
Figure 3: Product Comparison in Antihypertensive Drugs Market 2018-2019 (US$)
Figure 4: End User Profile for Antihypertensive Drugs Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Antihypertensive Drugs Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Antihypertensive Drugs Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Antihypertensive Drugs Market 2018-2019
Figure 8: Ecosystem Analysis in Antihypertensive Drugs Market 2018
Figure 9: Average Selling Price in Antihypertensive Drugs Market 2021-2026
Figure 10: Top Opportunites in Antihypertensive Drugs Market 2018-2019
Figure 11: Market Life Cycle Analysis in Antihypertensive Drugs Market
Figure 12: GlobalBy TypeAntihypertensive Drugs Market Revenue, 2021-2026 ($)
Figure 13: Global Antihypertensive Drugs Market - By Geography
Figure 14: Global Antihypertensive Drugs Market Value & Volume, By Geography, 2021-2026 ($)
Figure 15: Global Antihypertensive Drugs Market CAGR, By Geography, 2021-2026 (%)
Figure 16: North America Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 17: US Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 18: US GDP and Population, 2018-2019 ($)
Figure 19: US GDP – Composition of 2018, By Sector of Origin
Figure 20: US Export and Import Value & Volume, 2018-2019 ($)
Figure 21: Canada Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 22: Canada GDP and Population, 2018-2019 ($)
Figure 23: Canada GDP – Composition of 2018, By Sector of Origin
Figure 24: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Mexico Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 26: Mexico GDP and Population, 2018-2019 ($)
Figure 27: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29: South America Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 30: Brazil Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 31: Brazil GDP and Population, 2018-2019 ($)
Figure 32: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34: Venezuela Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 35: Venezuela GDP and Population, 2018-2019 ($)
Figure 36: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Argentina Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 39: Argentina GDP and Population, 2018-2019 ($)
Figure 40: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Ecuador Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 43: Ecuador GDP and Population, 2018-2019 ($)
Figure 44: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Peru Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 47: Peru GDP and Population, 2018-2019 ($)
Figure 48: Peru GDP – Composition of 2018, By Sector of Origin
Figure 49: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Colombia Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 51: Colombia GDP and Population, 2018-2019 ($)
Figure 52: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Costa Rica Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 55: Costa Rica GDP and Population, 2018-2019 ($)
Figure 56: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Europe Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 59: U.K Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 60: U.K GDP and Population, 2018-2019 ($)
Figure 61: U.K GDP – Composition of 2018, By Sector of Origin
Figure 62: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63: Germany Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 64: Germany GDP and Population, 2018-2019 ($)
Figure 65: Germany GDP – Composition of 2018, By Sector of Origin
Figure 66: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Italy Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 68: Italy GDP and Population, 2018-2019 ($)
Figure 69: Italy GDP – Composition of 2018, By Sector of Origin
Figure 70: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71: France Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 72: France GDP and Population, 2018-2019 ($)
Figure 73: France GDP – Composition of 2018, By Sector of Origin
Figure 74: France Export and Import Value & Volume, 2018-2019 ($)
Figure 75: Netherlands Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 76: Netherlands GDP and Population, 2018-2019 ($)
Figure 77: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Belgium Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 80: Belgium GDP and Population, 2018-2019 ($)
Figure 81: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Spain Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 84: Spain GDP and Population, 2018-2019 ($)
Figure 85: Spain GDP – Composition of 2018, By Sector of Origin
Figure 86: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Denmark Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 88: Denmark GDP and Population, 2018-2019 ($)
Figure 89: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91: APAC Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 92: China Antihypertensive Drugs Market Value & Volume, 2021-2026
Figure 93: China GDP and Population, 2018-2019 ($)
Figure 94: China GDP – Composition of 2018, By Sector of Origin
Figure 95: China Export and Import Value & Volume, 2018-2019 ($)Antihypertensive Drugs Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 96: Australia Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 97: Australia GDP and Population, 2018-2019 ($)
Figure 98: Australia GDP – Composition of 2018, By Sector of Origin
Figure 99: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100: South Korea Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 101: South Korea GDP and Population, 2018-2019 ($)
Figure 102: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104: India Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 105: India GDP and Population, 2018-2019 ($)
Figure 106: India GDP – Composition of 2018, By Sector of Origin
Figure 107: India Export and Import Value & Volume, 2018-2019 ($)
Figure 108: Taiwan Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 109: Taiwan GDP and Population, 2018-2019 ($)
Figure 110: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Malaysia Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 113: Malaysia GDP and Population, 2018-2019 ($)
Figure 114: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Hong Kong Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 117: Hong Kong GDP and Population, 2018-2019 ($)
Figure 118: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Middle East & Africa Antihypertensive Drugs Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 121: Russia Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 122: Russia GDP and Population, 2018-2019 ($)
Figure 123: Russia GDP – Composition of 2018, By Sector of Origin
Figure 124: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125: Israel Antihypertensive Drugs Market Value & Volume, 2021-2026 ($)
Figure 126: Israel GDP and Population, 2018-2019 ($)
Figure 127: Israel GDP – Composition of 2018, By Sector of Origin
Figure 128: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129: Entropy Share, By Strategies, 2018-2019* (%)Antihypertensive Drugs Market
Figure 130: Developments, 2018-2019*Antihypertensive Drugs Market
Figure 131: Company 1 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 132: Company 1 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 133: Company 1 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 134: Company 2 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 2 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 2 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 137: Company 3Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 138: Company 3Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 139: Company 3Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 140: Company 4 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 141: Company 4 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 142: Company 4 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 143: Company 5 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 144: Company 5 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 145: Company 5 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 146: Company 6 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 147: Company 6 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 148: Company 6 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 149: Company 7 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 150: Company 7 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 151: Company 7 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 152: Company 8 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 153: Company 8 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 154: Company 8 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 155: Company 9 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 156: Company 9 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 157: Company 9 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 158: Company 10 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 159: Company 10 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 160: Company 10 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 11 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 11 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 11 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 164: Company 12 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 165: Company 12 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 166: Company 12 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 167: Company 13Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 168: Company 13Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 169: Company 13Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 170: Company 14 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 171: Company 14 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 172: Company 14 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 173: Company 15 Antihypertensive Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 174: Company 15 Antihypertensive Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 175: Company 15 Antihypertensive Drugs Market Net Sales Share, By Geography, 2018 (%)